Normal cerebellar glutamate dehydrogenase protein in spinocerebellar degeneration

ROGER N ROSENBERG,* CARL BANNER†

From the Department of Neurology,* University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, and the Laboratory of Molecular Biology,† National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA

**SUMMARY** Immunochemical analyses (Western blots) of cerebellar homogenates for glutamate dehydrogenase (GDH) from patients with spinocerebellar degeneration and control subjects were conducted. Four patients with autosomal dominant Joseph disease type of spinocerebellar degeneration, one patient with autosomal dominant olivopontocerebellar degeneration and four control subjects were studied. GDH was of the same molecular weight and amount in all patients and control subjects. These data together with normal GDH activity from these same homogenates published previously support the view that GDH is not involved in the pathogenesis of these types of dominantly inherited spinocerebellar degeneration.

The primary biochemical defect in autosomal dominant Joseph disease (JD) and olivopontocerebellar atrophy (OPCA) is not known. A deficiency in fibroblast and leukocyte glutamate dehydrogenase (GDH) (EC 1.4.1.3) specific activity has been reported in autosomal recessive and autosomal dominant forms of OPCA. The protein content of leukocyte GDH was reported to be decreased in four of 14 patients studied with spinocerebellar degeneration (SCD) and the reduction in the protein content was proportional to that in the enzyme activity. We have reported normal mitochondrial and cytosolic GDH activity in cerebellar and cerebral cortex from OPCA and JD patients compared to control subjects. We follow up here on those studies by reporting the Western blot analysis of GDH in the cerebellum from JD and OPCA patients and control subjects.

**Materials and methods**

**Patient material**

Control brain samples were obtained from the Dallas County Medical Examiner’s Office through the courtesy of Dr Charles Petty, Chief Medical Examiner. Control patient 5 (numbered to correlate with the fig) was a 23 year old man who died of a gun shot wound. Control patient 6 was a 48 year old man who died in a car accident. Control patient 7 was a 33 year old man who died of a myocardial infarction. Control patient 8 was a 37 year old man who died of a gun shot wound. All brains were removed in the medical examiner’s office and frozen within 10 hours after death, and the bodies were refrigerated to 4°C within 2 hours after death.

Joseph disease brains were removed in local hospitals by attending pathologists within 5 hours after death. The bodies were refrigerated within 2 hours after death to 4°C; brain samples were frozen immediately at the time of necropsy.

JD patient 1 was a 43 year old man with disease for 15 years. JD patient 2 was a 58 year old man with disease for at least 20 years. JD patient 3 was a 60 year old man with disease for 20 years. JD patient 4 was a 75 year old man with disease for at least 10 years. OPCA patient 1 was a 55 year old man with symptoms for 15 years.

The brain was sent through the courtesy of Dr Larry Schut, Minneapolis, Minnesota. The patient was examined by Dr Schut and was a member of an established family with autosomal dominant OPCA.

All brain samples from control, JD, and OPCA patients were initially frozen on dry ice and then stored at −70°C.

**Immunoblot methods**

The tissue samples were homogenised on ice in 0.0625 M Tris, pH 6.8, 2% SDS, 10% glycerol, 5% 2-mercaptoethanol and then boiled for 3 minutes. Thirty µg of protein from each lysate was subjected to SDS-polyacrylamide gel electrophoresis. Protein concentration was determined by the Lowry assay after precipitation with trichloroacetic acid. The amount of protein applied to the gel was chosen so as to
be within the proportional range of alkaline phosphatase reactivity (data not shown). The proteins were electrobotted from the gel to a nitrocellulose filter. Monoclonal anti-GDH antibody was a kind gift of Dr A J Beitz. The nitrocellulose filters were incubated with this antibody as previously described by Wenthold et al. Detection of bound antibodies was by alkaline phosphatase conjugated antimouse IgG (Promega).

**Results**

GDH was identified by Western immunoblotting from four patients with JD, one patient with OPCA, and four control subjects. It had the same molecular weight (55 kD) in all subjects and was present equally in these cerebellar homogenates within the range of variability among the controls (fig).

**Discussion**

A deficiency in GDH was first described in patient fibroblast cultures by Plaitakis et al in a patient with autosomal recessive OPCA. Leukocytes from that patient also had decreased GDH activity. Subsequently, Plaitakis et al made similar observations in 88 other patients with different neurologic disorders. Twelve patients with progressive multiple-system atrophic disorders had partial deficiency of GDH (52% of control level). Seven of those patients with GDH deficiency had autosomal recessive patterns of inheritance, and five were sporadic. They found that it was essential to fractionate GDH; leukocyte GDH deficiency was limited to the particulate, heat-labile component (bound to a mitochondrial membrane) and was not found in the soluble, heat-stable component. They suggested that the magnitude of the decrease in the heat-labile GDH to 8% of control level was consistent with a recessively inherited primary enzymatic defect, and that a GDH isozyme defect was the primary mutation.

Plaitakis found normal GDH activity in autosomal dominant OPCA. However, Duvoisin et al found low leukocyte GDH in presumably dominantly inherited OPCA, with patients having 38% of normal GDH leukocyte specific activity. Finocchiaro et al studied GDH in leukocytes in 11 patients with dominantly inherited OPCA, in three patients with recessively inherited OPCA, and in one sporadic case. Leukocyte values were reduced to 68% of control and reduced to 46% in muscle mitochondria compared to control in the dominantly inherited OPCA patients. They found that an oral glutamate loading test produced higher plasma glutamate levels in patients compared with controls. They concluded that a subset of OPCA patients had a defect in mitochondrial glutamate metabolism.

We utilised cerebral cortical and cerebellar cortical frozen necropsy samples obtained from JD, OPCA, and control patients for GDH assays. There was no statistically significant difference in specific activity of mitochondrial or cytoplasmic GDH in OPCA or JD samples compared with control subject samples.

Recently, Kajiyama et al reported decreased GDH protein in leukocytes in patients with SCD or atypical Parkinsonism. The protein content of leukocyte
GDH was decreased in only four patients of 14 studied and the reduction in the protein content was proportional to that in the enzyme activity. Thus, a subset of patients with SCD or atypical Parkinsonism had reduced GDH activity and protein as measured by radioimmunoassay.

We followed up on our previously published observations on cerebellar GDH activity in SCD by immunocochemically assaying (Western immunoblot) patient and control GDH from cerebellar homogenates. As seen in the fig, these studies showed normal molecular weight and amount of GDH in JD patients and in an OPCA dominantly inherited patient compared to control subjects. Thus, both cerebellar GDH activity and protein amount were within a normal range in these patients with SCD as compared with control subjects. It is our view based on these data that GDH is not involved in dominantly inherited JD and OPCA.

We express our gratitude to Dr A J Beitz for monoclonal anti-GDH antisera and to Mrs Sally Gagne for technical assistance.

References


Normal cerebellar glutamate dehydrogenase protein in spinocerebellar degeneration.

R N Rosenberg and C Banner

*J Neurol Neurosurg Psychiatry* 1989 52: 666-668
doi: 10.1136/jnnp.52.5.666

Updated information and services can be found at:
[http://jnnp.bmj.com/content/52/5/666](http://jnnp.bmj.com/content/52/5/666)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)